GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

GSK plc. GSK will report first-quarter 2024 results ... In the first quarter, higher sales of newer products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix are likely to ...

In comparison, I expect it to be $1.05, which is above the midpoint of the above range due to stronger sales of Cabenuva, Jemperli, Ojjaara/Omjjara, and Dovato. Was Emma Walmsley, CEO of GSK ...

GSK’s Specialty Medicines Drive Top Line HIV sales rose 14% during the quarter, driven by strong patient demand for the company’s two-drug regimens — Dovato and J&J JNJ-partnered Juluca ...

PHILADELPHIA, February 17, 2025--PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY ViiV Healthcare, the global specialist HIV company majority ...

GSK has counted the cost of narrower US recommendations on the use of RSV vaccines, which caused a 51% decline in sales of its Arexvy shot in 2024, but still managed to post reasonable sales ...

Dovato (dolutegravir/lamivudine) is a prescription drug that’s used to treat HIV. The drug comes as a tablet that you swallow. It’s usually taken once per day ...

HIV sales rose 14% driven by strong demand and increased market share for oral two-drug regimens, Dovato and Juluca, and long-acting regimens like Cabenuva and Apretude. GSK generates the ...